Friday , October 20 2017
Home / KEEP BUT DO NOT DISPLAY / Did You Know / Insulin May Increase CV Risk for Type 2’s More than a DPP-4 Inhibitor

Insulin May Increase CV Risk for Type 2’s More than a DPP-4 Inhibitor

A retrospective study of patients with type 2 diabetes taking metformin and sulfonylureas and newly treated with either a dipeptidyl peptidase 4 (DPP-4) inhibitor or insulin as third-line therapy has found that adding insulin was associated with an increased risk of cardiovascular events compared with a DPP-4 inhibitor. For the composite outcome of nonfatal acute myocardial infarction, nonfatal stroke or all-cause mortality, there were 231 events among those on insulin compared with 171 for those taking DPP-4 inhibitors. There were 95 cardiovascular events among those on insulin compared with 94 in those taking a DPP-4 inhibitor. And there were 124 all-cause deaths among those taking insulin compared with 64 among those taking DPP-4 inhibitors. — Diabetes UK Professional Conference, March, 2015, London, Abstract A4 (P2777)